Summary table
| Condition | Age Group | Patient Population | Dosage | Duration | Results |
|---|---|---|---|---|---|
| Hypoxic ischemic brain injury | Premature infants aged 6–12 months |
87 patients (44 standard + Hopantenic acid, 43 standard + placebo) |
Hopantenic acid syrup (100 mg/ml), 2× a day, 30–50 mg/kg/day. |
2 months |
|
| Cerebral Palsy with cognitive impairment | Children & adolescents aged 8–14 years |
100 patients (50 Hopantenic acid + basic therapy, 50 basic therapy only) |
Hopantenic acid 1000–1500 mg/day (30–50 mg/kg), oral, 2×/day. |
3 months |
|
| ADHD | Children aged 6–12 years |
100 patients (50 Hopantenic acid, 50 placebo; 89 completed) |
Hopantenic acid tablets 250 mg, 30 mg/kg/day, 2×/day. |
4 months |
WFIRS-P scale:
|
| Epilepsy with cognitive impairment | Children aged 4–7 years |
63 patients (40 Hopantenic acid, 23 control) |
Hopantenic acid 20–30 mg/kg/day |
2 months |
|
| Tic disorders | Children aged 10–17 years |
43 patients (Hopantenic acid), 20 healthy controls |
Hopantenic acid 500 mg, 3×/day |
6 weeks |
|
| Affective-respiratory paroxysms (breath-holding spells) |
Children aged 2–4 years |
60 patients (30 Hopantenic acid, 30 psychological therapy only) |
Hopantenic acid syrup 100 mg/ml, 30–35 mg/kg/day |
3 months |
|
PUBLICATION
Explore the research and review publications on hopantenic acid
in pediatric neurological and developmental disorders.
Meta Analysis
Efficacy and Safety of Hopantenic Acid inPediatric Neurological and
DevelopmentalDisorders: A Systematic Review and Meta-Analysis
Attention-Deficit/Hyperactivity Disorder(ADHD)
Pharmacotherapy of Attention Deficit Hyperactivity Disorder in Children: Results of a Multicenter, Double-Blind, Placebo-Controlled Trial of Hopantenic Acid
HYPOXIC
Pharmacotherapy of psychomotor developmental delay in children aged 6-12 months, born prematurely and having suffered hypoxic-ischemic brain injury (double-blind comparative multicenter study) placebo-controlled study
Epilepsy
Diagnosis and correction of cognitive impairment in preschool children with epilepsy
Cerebral Palsy
Hopantenic Acid and Cognitive Function in Children With Cerebral Palsy
TICS
METHODS OF OBJECTIVE CONTROL OF THERAPY EFFECTIVENESS In children with TICS
Affective- Respirtatory
Use of the drug pantogam syrup in the treatment of affective-respiratory paroxysms in young children
This is a title
Type your paragraph here
Meta Analysis
Efficacy and Safety of Hopantenic Acid inPediatric Neurological and
DevelopmentalDisorders: A Systematic Review and Meta-Analysis
Attention-Deficit/Hyperactivity Disorder(ADHD)
Pharmacotherapy of Attention Deficit Hyperactivity Disorder in Children: Results of a Multicenter, Double-Blind, Placebo-Controlled Trial of Hopantenic Acid
HYPOXIC
Pharmacotherapy of psychomotor developmental delay in children aged 6-12 months, born prematurely and having suffered hypoxic-ischemic brain injury (double-blind comparative multicenter study) placebo-controlled study
Epilepsy
Diagnosis and correction of cognitive impairment in preschool children with epilepsy
Cerebral Palsy
Hopantenic Acid and Cognitive Function in Children With Cerebral Palsy
TICS
METHODS OF OBJECTIVE CONTROL OF THERAPY EFFECTIVENESS In children with TICS
Affective- Respirtatory
Use of the drug pantogam syrup in the treatment of affective-respiratory paroxysms in young children
This is a title
Type your paragraph here